Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 19/20 | 0.86 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.86 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.86 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.46 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.46 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13283903 | 0.93 | LPAR1 (0.76) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL3841276 | 0.93 | LPAR1 (1.00) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032471 | 0.93 | LPAR1 (0.79) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032900 | 0.91 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4030950 | 0.91 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032482 | 0.91 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4029152 | 0.91 | LPAR1 (0.71) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4029832 | 0.90 | LPAR1 (0.71) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4031278 | 0.90 | LPAR1 (0.86) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4030185 | 0.89 | LPAR1 (0.82) | LPAR1LPAR3LPAR2ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| US-20240285587-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2024-08-29 | — | — | US | claimed |
| CN-118055777-A | Novel therapeutic agent for inhibiting metastasis and proliferation of osteosarcoma and glioma | 公益财团法人癌研究会 | 2024-05-17 | — | — | CN | claimed |
| EP-4360650-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | Japanese Foundation For Cancer Research (JP) | 2024-05-01 | — | — | EP | claimed |
| WO-2022270621-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | 公益財団法人がん研究会 | 2022-12-29 | — | — | WO | claimed |
| EP-1364659-B1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-1258484-B1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20080234230-A1 | Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-25 | — | — | US | claimed |
| EP-1415667-B1 | PANCREATIC JUICE SECRETION REGULATORS COMPRISING LPA RECEPTOR CONTROLLER | ONO PHARMACEUTICAL CO (JP) | 2008-09-03 | — | — | EP | claimed |
| US-7288558-B2 | Pharmaceutical composition for treatment for urinary diseases comprising LPA receptor regulator | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-30 | — | — | US | claimed |
| US-6964975-B2 | Isoxazole and thiazole compounds and use thereof as medicine | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-11-15 | — | — | US | claimed |
| US-20040171582-A1 | Pancreatic juice secretion regulators comprising lpa receptor controller | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-02 | — | — | US | claimed |
| EP-1415667-A1 | PANCREATIC JUICE SECRETION REGULATORS COMPRISING LPA RECEPTOR CONTROLLER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-20040067908-A1 | Remedies for urinary diseases comprising lpa receptor controlling agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | claimed |
| EP-1364659-A1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-26 | — | — | EP | claimed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| EP-1364659-A1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030114505-A1 | Novel isoxazole and thiazole compounds and use thereof as drugs | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1258484-A1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067908-A1 | Remedies for urinary diseases comprising lpa receptor controlling agents | LPAR1, LPAR2, LPAR6 | LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885 |
| US-20040171582-A1 | Pancreatic juice secretion regulators comprising lpa receptor controller | GPR119, LPAR1, LPAR5 | LPAR1 2/4885LPAR3 5/4885LPAR2 4/4885 |
| US-20030114505-A1 | Novel isoxazole and thiazole compounds and use thereof as drugs | LPAR3, LPAR1, LPAR4 | LPAR1 2/4885LPAR3 1/4885LPAR2 4/4885 |
| US-20080234230-A1 | Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator | GPR119, LPAR5, LPAR1 | LPAR1 3/4885LPAR3 5/4885LPAR2 6/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | LPAR1 1690/4885LPAR3 1366/4885LPAR2 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.